Denali Therapeutics Inc
NASDAQ:DNLI 3:59:40 PM EDT
| Market Cap (Intraday) | 6.86B |
| Current PE | 96.41 |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $61.17 |
| 50-Day MA | $71.15 |
| 200-Day MA | $48.15 |
Denali Therapeutics, Inc. Stock, NASDAQ:DNLI
161 Oyster Point Boulevard, 2nd Floor, San Francisco, California 94080
United States of America
Phone: +1.615.866.8548
Number of Employees: 261
Description
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.